Adeona Pharmaceuticals Expands Patent Estate for Oral TRIMESTA Through an Option Agreement With University of Kansas

ANN ARBOR, MI--(Marketwire - December 15, 2008) - Adeona Pharmaceuticals, Inc. (AMEX: AEN), a specialty pharmaceutical company developing innovative clinical-stage drug candidates for the treatment of autoimmune and central nervous system diseases, announced today that it has expanded its intellectual property estate through an option agreement to license with the University of Kansas relating to various uses of oral estriol for the treatment of various immunomodulatory diseases. TRIMESTA (oral, once-daily estriol) is being developed in an ongoing double-blind, phase IIb clinical trial for the treatment of relapsing remitting multiple sclerosis.